Reduced Endothelium-dependent Relaxation to Anandamide in Mesenteric Arteries from Young Obese Zucker Rats

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 May 14

PMID 23667622

Citations 12

Authors

Nubia S Lobato

Fernando P Filgueira

Roshini Prakash

Fernanda R Giachini

Adviye Ergul

Maria Helena C Carvalho

R Clinton Webb

Rita C Tostes

Zuleica B Fortes

Affiliations

Soon will be listed here.

Abstract

Impaired vascular function, manifested by an altered ability of the endothelium to release endothelium-derived relaxing factors and endothelium-derived contracting factors, is consistently reported in obesity. Considering that the endothelium plays a major role in the relaxant response to the cannabinoid agonist anandamide, the present study tested the hypothesis that vascular relaxation to anandamide is decreased in obese rats. Mechanisms contributing to decreased anandamide-induced vasodilation were determined. Resistance mesenteric arteries from young obese Zucker rats (OZRs) and their lean counterparts (LZRs) were used. Vascular reactivity was evaluated in a myograph for isometric tension recording. Protein expression and localization were analyzed by Western blotting and immunofluorescence, respectively. Vasorelaxation to anandamide, acetylcholine, and sodium nitroprusside, as well as to CB1, CB2, and TRPV1 agonists was decreased in endothelium-intact mesenteric arteries from OZRs. Incubation with an AMP-dependent protein kinase (AMPK) activator or a fatty acid amide hydrolase inhibitor restored anandamide-induced vascular relaxation in OZRs. CB1 and CB2 receptors protein expression was decreased in arteries from OZRs. Incubation of mesenteric arteries with anandamide evoked endothelial nitric oxide synthase (eNOS), AMPK and acetyl CoA carboxylase phosphorylation in LZRs, whereas it decreased phosphorylation of these proteins in OZRs. In conclusion, obesity decreases anandamide-induced relaxation in resistance arteries. Decreased cannabinoid receptors expression, increased anandamide degradation, decreased AMPK/eNOS activity as well as impairment of the response mediated by TRPV1 activation seem to contribute to reduce responses to cannabinoid agonists in obesity.

Citing Articles

Vascular Dysfunction in Diabetes and Obesity: Focus on TRP Channels.

Moraes R, Webb R, Flavia Silva D Front Physiol. 2021; 12:645109.

PMID: 33716794 PMC: 7952965. DOI: 10.3389/fphys.2021.645109.

A cannabinoid type 2 (CB2) receptor agonist augments NOS-dependent responses of cerebral arterioles during type 1 diabetes.

Van Hove L, Kim K, Arrick D, Mayhan W Microvasc Res. 2020; 133:104077.

PMID: 32979391 PMC: 7704564. DOI: 10.1016/j.mvr.2020.104077.

Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet.

Sukumaran V, Tsuchimochi H, Sonobe T, Waddingham M, Shirai M, Pearson J Cardiovasc Diabetol. 2020; 19(1):24.

PMID: 32093680 PMC: 7038553. DOI: 10.1186/s12933-020-01000-z.

Synthesis, physicochemical characterisation and biological activity of anandamide/ɛ-polycaprolactone nanoparticles obtained by electrospraying.

Martin Gimenez V, Russo M, Narda G, Fuentes L, Mazzei L, Gamarra-Luques C IET Nanobiotechnol. 2020; 14(1):86-93.

PMID: 31935683 PMC: 8676047. DOI: 10.1049/iet-nbt.2019.0108.

Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease.

Gimenez V, Noriega S, Kassuha D, Fuentes L, Manucha W Ther Adv Cardiovasc Dis. 2018; 12(7):177-190.

PMID: 29764302 PMC: 6009078. DOI: 10.1177/1753944718773690.

References

Deutsch D, Goligorsky M, Schmid P, Krebsbach R, SCHMID H, Das S . Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 1997; 100(6):1538-46. PMC: 508335. DOI: 10.1172/JCI119677. View

Flegal K, Carroll M, Ogden C, Johnson C . Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002; 288(14):1723-7. DOI: 10.1001/jama.288.14.1723. View

Holzer P . Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev. 1991; 43(2):143-201. View

Di Marzo V . Targeting the endocannabinoid system: to enhance or reduce?. Nat Rev Drug Discov. 2008; 7(5):438-55. DOI: 10.1038/nrd2553. View

Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M . The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003; 112(3):423-31. PMC: 166293. DOI: 10.1172/JCI17725. View

Subramanian R, MacLeod K . Age-dependent changes in blood pressure and arterial reactivity in obese Zucker rats. Eur J Pharmacol. 2003; 477(2):143-52. DOI: 10.1016/j.ejphar.2003.08.003. View

Liu J, Wang L, Harvey-White J, Huang B, Kim H, Luquet S . Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology. 2007; 54(1):1-7. PMC: 2219543. DOI: 10.1016/j.neuropharm.2007.05.020. View

Gardiner S, March J, Kemp P, Bennett T . Factors influencing the regional haemodynamic responses to methanandamide and anandamide in conscious rats. Br J Pharmacol. 2009; 158(4):1143-52. PMC: 2785535. DOI: 10.1111/j.1476-5381.2009.00363.x. View

Matias I, Petrosino S, Racioppi A, Capasso R, Izzo A, Di Marzo V . Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol. 2008; 286(1-2 Suppl 1):S66-78. DOI: 10.1016/j.mce.2008.01.026. View

10.

Zygmunt P, Petersson J, Andersson D, Chuang H, Sorgard M, Di Marzo V . Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999; 400(6743):452-7. DOI: 10.1038/22761. View

11.

Moncada S, Rees D, Schulz R, Palmer R . Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A. 1991; 88(6):2166-70. PMC: 51190. DOI: 10.1073/pnas.88.6.2166. View

12.

Dray A, Forbes C, Burgess G . Ruthenium red blocks the capsaicin-induced increase in intracellular calcium and activation of membrane currents in sensory neurones as well as the activation of peripheral nociceptors in vitro. Neurosci Lett. 1990; 110(1-2):52-9. DOI: 10.1016/0304-3940(90)90786-9. View

13.

Gunthorpe M, Benham C, Randall A, Davis J . The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci. 2002; 23(4):183-91. DOI: 10.1016/s0165-6147(02)01999-5. View

14.

ZUCKER L, Antoniades H . Insulin and obesity in the Zucker genetically obese rat "fatty". Endocrinology. 1972; 90(5):1320-30. DOI: 10.1210/endo-90-5-1320. View

15.

Chen Z, Mitchelhill K, Michell B, Stapleton D, Rodriguez-Crespo I, Witters L . AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999; 443(3):285-9. DOI: 10.1016/s0014-5793(98)01705-0. View

16.

Echahidi N, Mohty D, Pibarot P, Despres J, OHara G, Champagne J . Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation. 2007; 116(11 Suppl):I213-9. DOI: 10.1161/CIRCULATIONAHA.106.681304. View

17.

Wheal A, Bennett T, Randall M, Gardiner S . Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol. 2007; 152(5):717-24. PMC: 2190006. DOI: 10.1038/sj.bjp.0707410. View

18.

Scotland R, Chauhan S, Davis C, de Felipe C, Hunt S, Kabir J . Vanilloid receptor TRPV1, sensory C-fibers, and vascular autoregulation: a novel mechanism involved in myogenic constriction. Circ Res. 2004; 95(10):1027-34. DOI: 10.1161/01.RES.0000148633.93110.24. View

19.

Wagner J, Hu K, Bauersachs J, KARCHER J, Wiesler M, Goparaju S . Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol. 2001; 38(7):2048-54. DOI: 10.1016/s0735-1097(01)01671-0. View

20.

Mukhopadhyay P, Batkai S, Rajesh M, Czifra N, Harvey-White J, Hasko G . Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 2007; 50(6):528-36. PMC: 2239316. DOI: 10.1016/j.jacc.2007.03.057. View